IP Group

IP Group is a London-based corporate firm that provides financial, strategic, and commercial expertise to clients internationally. Founded in 2001, the company focuses on creating value through the commercialisation of intellectual property derived from research-intensive institutions. It manages the end-to-end process of identifying viable IP, developing or partnering to build value, and establishing commercial arrangements that translate scientific advances into practical products and businesses. IP Group combines industry insight and financial experience to support science- and technology-based ventures, offering capital as well as strategic guidance to help companies grow and accelerate the impact of research. Its work spans clean technology, life sciences, and other deep technology sectors, with a track record of backing and developing ventures that aim to deliver tangible societal and economic outcomes.

Alan Aubrey

CEO

David Baynes

Chief Financial and Operating Officer

Jon Edington

Partner, Technology

Michael Molinari Ph.D

Managing Director

Ben Murphey

Investment Director

Past deals in 3D Printing

AudioScenic

Series A in 2023
AudioScenic specializes in developing advanced 3D audio technology using small speaker arrays and head tracking. This enables immersive, personalized sound experiences without the need for headphones or multiple speakers, benefiting industries such as gaming, cinema, VR, and automotive.

Ultraleap

Series D in 2021
Ultraleap specializes in developing and commercializing innovative haptic control systems. Founded in 2013, the company is renowned for its mid-air haptics and 3D hand tracking technologies. Ultraleap's solutions include Leap Motion Controller for optical hand tracking, VR Developer Mount for virtual reality experiences, and Gemini, a hand tracking platform. Its applications span across extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment.

AudioScenic

Series A in 2020
AudioScenic specializes in developing advanced 3D audio technology using small speaker arrays and head tracking. This enables immersive, personalized sound experiences without the need for headphones or multiple speakers, benefiting industries such as gaming, cinema, VR, and automotive.

AudioScenic

Seed Round in 2019
AudioScenic specializes in developing advanced 3D audio technology using small speaker arrays and head tracking. This enables immersive, personalized sound experiences without the need for headphones or multiple speakers, benefiting industries such as gaming, cinema, VR, and automotive.

Ultraleap

Series C in 2018
Ultraleap specializes in developing and commercializing innovative haptic control systems. Founded in 2013, the company is renowned for its mid-air haptics and 3D hand tracking technologies. Ultraleap's solutions include Leap Motion Controller for optical hand tracking, VR Developer Mount for virtual reality experiences, and Gemini, a hand tracking platform. Its applications span across extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment.

OxSyBio

Series A in 2018
OxSyBio Ltd. is a biotechnology company based in London, United Kingdom, specializing in the development of advanced 3D printing techniques for creating tissue-like and functional tissues intended for medical research and clinical applications. Founded in 2014, the company focuses on innovative methods that utilize three-dimensional networks of lipid monolayer aqueous droplets, which can conduct electrical signals along designated pathways and self-fold into intricate structures. These engineered tissues aim to facilitate organ repair or replacement, supporting precision medicine initiatives. The technology builds upon pioneering research from Professor Hagan Bayley's group at the University of Oxford, emphasizing the integration of chemical and synthetic biology in the field of regenerative medicine.

Ultraleap

Series B in 2017
Ultraleap specializes in developing and commercializing innovative haptic control systems. Founded in 2013, the company is renowned for its mid-air haptics and 3D hand tracking technologies. Ultraleap's solutions include Leap Motion Controller for optical hand tracking, VR Developer Mount for virtual reality experiences, and Gemini, a hand tracking platform. Its applications span across extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment.

Ultraleap

Series A in 2015
Ultraleap specializes in developing and commercializing innovative haptic control systems. Founded in 2013, the company is renowned for its mid-air haptics and 3D hand tracking technologies. Ultraleap's solutions include Leap Motion Controller for optical hand tracking, VR Developer Mount for virtual reality experiences, and Gemini, a hand tracking platform. Its applications span across extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment.

Ultraleap

Seed Round in 2014
Ultraleap specializes in developing and commercializing innovative haptic control systems. Founded in 2013, the company is renowned for its mid-air haptics and 3D hand tracking technologies. Ultraleap's solutions include Leap Motion Controller for optical hand tracking, VR Developer Mount for virtual reality experiences, and Gemini, a hand tracking platform. Its applications span across extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment.

OxSyBio

Seed Round in 2014
OxSyBio Ltd. is a biotechnology company based in London, United Kingdom, specializing in the development of advanced 3D printing techniques for creating tissue-like and functional tissues intended for medical research and clinical applications. Founded in 2014, the company focuses on innovative methods that utilize three-dimensional networks of lipid monolayer aqueous droplets, which can conduct electrical signals along designated pathways and self-fold into intricate structures. These engineered tissues aim to facilitate organ repair or replacement, supporting precision medicine initiatives. The technology builds upon pioneering research from Professor Hagan Bayley's group at the University of Oxford, emphasizing the integration of chemical and synthetic biology in the field of regenerative medicine.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.